ONL Therapeutics
PrivateLast Round
Series D
Sep 13, 2024
Total Funding Raised
$151.72M
Company Overview
ONL Therapeutics operates in Healthcare & Life Sciences and is based in Ann Arbor, Michigan. Its latest recorded funding round was a Series D round in September 2024.
ONL Therapeutics is a biopharmaceutical company that develops first-in-class therapeutics to protect and improve the vision of patients with retinal diseases and conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ONL Therapeutics Comparables
Compare ONL Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Astellas Pharma Inc. | 80% | |
| Aviceda Therapeutics | 80% | |
| Kyoto Drug Discovery & Development Co., Ltd. | 78% |
For institutional investors. Book with your work email.
ONL Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 13, 2024 | ||||
| VC Round | Mar 12, 2024 | ||||
| Series C | Aug 1, 2023 | ||||
| Series C | Mar 8, 2023 | ||||
| Series B | Dec 22, 2020 | ||||
Convertible Debt | Aug 22, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ONL Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| PSQ Capital | Series B |
| National Eye Institute (NIH) | Grant |
| Kaitai Capital | Series C, Series B |
| Hestia Investments | Series A |
| Biosciences Research & Commercialization Center | Convertible Debt, Series C, Series B, Series A |
| Michigan Investment in New Technology Startups | Convertible Debt, Series B, Series C, Series A |
| Mayewell Capital | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2025
Presented at the FLORetina-ICOOR Congress 2025.
- Nov 10, 2025
Will present at the EYENOVATE conference.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventAug 10, 2026
Lindsay Puscas of ONL Therapeutics, Inc. is to keynote The Business of Life Sciences at a2Tech360 at the Kensington Hotel in Michigan on Sep 29th '26.
For institutional investors. Book with your work email.
ONL Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ONL Therapeutics's valuation, stock price, and market status.
Is ONL Therapeutics a public or private company?
ONL Therapeutics is a private company.
What is the current stock price of ONL Therapeutics?
ONL Therapeutics is a private company, so its shares have no public market price. Caplight tracks ONL Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ONL Therapeutics worth (valuation)?
Valuation information for ONL Therapeutics is not publicly available.
Can I buy ONL Therapeutics stock?
ONL Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ONL Therapeutics's last funding round?
ONL Therapeutics's most recent funding round was Series D on September 13, 2024.
Who are the main investors in ONL Therapeutics?
Key investors in ONL Therapeutics include Michigan Investment in New Technology Startups, Johnson & Johnson Innovation – JJDC, InFocus Capital Partners, Johnson & Johnson Innovation - JJDC, Inc., Bios Partners.
Will ONL Therapeutics IPO soon?
No public IPO plans have been announced for ONL Therapeutics.
How can I track ONL Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in ONL Therapeutics's shares on secondary markets.